ArticleNature communications2019

The targetable kinase PIM1 drives ALK inhibitor resistance in high-risk neuroblastoma independent of MYCN status.

Ricky M Trigg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.